A prospective clinical study for osimertinib plus apatinib in patients with T790M-positive advanced NSCLC
Latest Information Update: 01 Oct 2019
At a glance
- Drugs Osimertinib (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Oct 2019 New trial record